JP2013530942A - 移行型小胞体ａｔｐアーゼの阻害のための方法および組成物 - Google Patents

移行型小胞体ａｔｐアーゼの阻害のための方法および組成物 Download PDF

Info

Publication number
JP2013530942A
JP2013530942A JP2013510192A JP2013510192A JP2013530942A JP 2013530942 A JP2013530942 A JP 2013530942A JP 2013510192 A JP2013510192 A JP 2013510192A JP 2013510192 A JP2013510192 A JP 2013510192A JP 2013530942 A JP2013530942 A JP 2013530942A
Authority
JP
Japan
Prior art keywords
formula
compound
alkyl
groups listed
methyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2013510192A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013530942A5 (enExample
Inventor
レイモンド ジェイ． デシャイーズ
ツイ―フェン チョウ
フランク ジェイ． シェーネン
ケリン リ
ケビン ジェイ． フランコウスキ
ジェフリー オーブ
サムエル ダブリュー． ジェリッツ
ハン―ジー チョウ
Original Assignee
カリフォルニア・インスティチュート・オブ・テクノロジー
ザ・ユニバーシティ・オブ・カンザス
クリーブ バイオサイエンシズ インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by カリフォルニア・インスティチュート・オブ・テクノロジー, ザ・ユニバーシティ・オブ・カンザス, クリーブ バイオサイエンシズ インコーポレイテッド filed Critical カリフォルニア・インスティチュート・オブ・テクノロジー
Publication of JP2013530942A publication Critical patent/JP2013530942A/ja
Publication of JP2013530942A5 publication Critical patent/JP2013530942A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
    • C12Q1/42—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving phosphatase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/48—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase
    • C12Q1/485—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase involving kinase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/02—Screening involving studying the effect of compounds C on the interaction between interacting molecules A and B (e.g. A = enzyme and B = substrate for A, or A = receptor and B = ligand for the receptor)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
JP2013510192A 2010-05-07 2011-05-06 移行型小胞体ａｔｐアーゼの阻害のための方法および組成物 Pending JP2013530942A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US33266710P 2010-05-07 2010-05-07
US61/332,667 2010-05-07
PCT/US2011/035654 WO2011140527A2 (en) 2010-05-07 2011-05-06 Methods and compositions for inhibition of the transitional endoplasmic reticulum atpase

Publications (2)

Publication Number Publication Date
JP2013530942A true JP2013530942A (ja) 2013-08-01
JP2013530942A5 JP2013530942A5 (enExample) 2014-06-26

Family

ID=44904519

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2013510192A Pending JP2013530942A (ja) 2010-05-07 2011-05-06 移行型小胞体ａｔｐアーゼの阻害のための方法および組成物

Country Status (8)

Country Link
US (1) US8865708B2 (enExample)
EP (1) EP2566480A4 (enExample)
JP (1) JP2013530942A (enExample)
KR (1) KR20130128308A (enExample)
CN (1) CN103068393A (enExample)
AU (1) AU2011249859B2 (enExample)
CA (1) CA2798698A1 (enExample)
WO (1) WO2011140527A2 (enExample)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8865708B2 (en) 2010-05-07 2014-10-21 California Institute Of Technology Methods and compositions for inhibition of the transitional endoplasmic reticulum ATPase
JP2017505812A (ja) * 2014-01-20 2017-02-23 クリーブ バイオサイエンシズ インコーポレイテッド ｐ９７複合体の阻害剤としての縮合ピリミジン
JP2017513874A (ja) * 2014-04-23 2017-06-01 ビーエーエスエフ ソシエタス・ヨーロピアＢａｓｆ Ｓｅ 除草剤としてのジアミノトリアジン化合物
JP2022522778A (ja) * 2019-03-01 2022-04-20 レボリューション メディシンズ インコーポレイテッド 二環式ヘテロシクリル化合物及びその使用

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8906918B1 (en) * 2012-03-23 2014-12-09 University Of South Florida (A Florida Non-Profit Corporation) Compositions, methods of use, and methods of treatment
EP2875018B1 (en) 2012-07-20 2018-02-14 Cleave Biosciences, Inc. FUSED PYRIMIDINES AS INHIBITORS OF p97 COMPLEX
JP2016504365A (ja) * 2012-12-28 2016-02-12 アメリカ合衆国 Ｕｓｐ１／ｕａｆ１デユビキチナーゼ複合体阻害剤及びその使用
PL3022191T3 (pl) 2013-07-16 2017-08-31 Basf Se Chwastobójcze azyny
DE102013110714A1 (de) * 2013-09-27 2015-04-02 Eberhard Karls Universität Tübingen Medizinische Fakultät Prophylaxe und Behandlung einer nicht auf einer Proteinfaltungsstörung beruhenden neurodegenerativen Erkrankung
EP3057592B1 (en) 2013-10-18 2019-05-22 Indiana University Research and Technology Corporation Hepatitis b viral assembly effectors
TW201605832A (zh) 2013-12-10 2016-02-16 克立弗生物科學公司 作為ｐ９７錯合物之抑制劑之單環嘧啶／吡啶化合物
WO2015155272A1 (en) 2014-04-11 2015-10-15 Basf Se Diaminotriazine derivatives as herbicides
CN106232586A (zh) * 2014-04-23 2016-12-14 巴斯夫欧洲公司 二氨基三嗪化合物及其作为除草剂的用途
CN107922377A (zh) 2015-04-17 2018-04-17 美国印第安纳大学研究和技术公司 乙肝病毒组装效应子
CN106518849B (zh) * 2016-10-27 2019-08-16 上海人类基因组研究中心 喹唑啉类化合物及其制备方法和用途
WO2024101336A1 (ja) * 2022-11-07 2024-05-16 国立大学法人京都大学 含窒素複素環化合物

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2071484T3 (es) * 1991-02-20 1995-06-16 Pfizer Derivados de 2,4-diaminoquinazolinas para aumentar la actividad antitumoral.
AU2002361846A1 (en) * 2001-12-21 2003-07-15 Bayer Pharmaceuticals Corporation Quinazoline and quinoline derivative compounds as inhibitors of prolylpeptidase, inducers of apoptosis and cancer treatment agents
AU2003255482A1 (en) 2002-10-02 2004-04-23 Merck Patent Gmbh Use of 4 amino-quinazolines as anti cancer agents
JP2008505907A (ja) * 2004-07-06 2008-02-28 アンジオン バイオメディカ コーポレイション 癌治療を目的として肝細胞増殖因子およびｃ−ｍｅｔ活性を調整するキナゾリンモジュレーター
WO2006105056A2 (en) 2005-03-28 2006-10-05 Fmc Corporation Insecticidal 2,4-diaminoquinazolines and related derivatives
WO2007041282A2 (en) 2005-09-29 2007-04-12 The Johns Hopkins University Methods and compositions for treatment of cystic fibrosis
WO2008157500A1 (en) * 2007-06-17 2008-12-24 Kalypsys, Inc. Aminoquinazoline cannabinoid receptor modulators for treatment of disease
US20100317607A1 (en) * 2007-06-27 2010-12-16 Infectious Disease Research Institute Use of compounds for preparing anti-tuberculosis agents
WO2009011910A2 (en) 2007-07-18 2009-01-22 Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Serices Imidazolidinone compounds, methods to inhibit deubiquitination and methods of treatment
US9089572B2 (en) 2008-01-17 2015-07-28 California Institute Of Technology Inhibitors of p97
WO2010003908A1 (en) 2008-07-08 2010-01-14 Jakobsson, Andreas Screening assay for compounds targeting the p97 aaa-atpase complex in the ubiquitin proteasome system.
US8865708B2 (en) 2010-05-07 2014-10-21 California Institute Of Technology Methods and compositions for inhibition of the transitional endoplasmic reticulum ATPase

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8865708B2 (en) 2010-05-07 2014-10-21 California Institute Of Technology Methods and compositions for inhibition of the transitional endoplasmic reticulum ATPase
JP2017505812A (ja) * 2014-01-20 2017-02-23 クリーブ バイオサイエンシズ インコーポレイテッド ｐ９７複合体の阻害剤としての縮合ピリミジン
JP2017513874A (ja) * 2014-04-23 2017-06-01 ビーエーエスエフ ソシエタス・ヨーロピアＢａｓｆ Ｓｅ 除草剤としてのジアミノトリアジン化合物
JP2022522778A (ja) * 2019-03-01 2022-04-20 レボリューション メディシンズ インコーポレイテッド 二環式ヘテロシクリル化合物及びその使用

Also Published As

Publication number Publication date
AU2011249859A1 (en) 2012-12-20
US20110288082A1 (en) 2011-11-24
EP2566480A4 (en) 2014-03-19
AU2011249859B2 (en) 2014-07-03
US8865708B2 (en) 2014-10-21
CA2798698A1 (en) 2011-11-10
WO2011140527A3 (en) 2012-03-29
EP2566480A2 (en) 2013-03-13
CN103068393A (zh) 2013-04-24
WO2011140527A2 (en) 2011-11-10
KR20130128308A (ko) 2013-11-26

Similar Documents

Publication Publication Date Title
JP2013530942A (ja) 移行型小胞体ａｔｐアーゼの阻害のための方法および組成物
EP2809324B1 (en) Cdk8/cdk19 selective inhibitors and their use in anti-metastatic and chemopreventive methods for cancer
CA2754808C (en) Prodrug forms of kinase inhibitors and their use in therapy
JP5897566B2 (ja) 環式ｎ，ｎ’−ジアリールチオ尿素及びｎ，ｎ’−ジアリール尿素−アンドロゲン受容体アンタゴニスト、抗癌剤、その調製のための方法及び使用
AU2014240003B2 (en) Coumarin derivatives and methods of use in treating hyperproliferative diseases
EP2935244A2 (en) Novel benzimidazole derivatives as kinase inhibitors
US20240199636A1 (en) Inhibitors of RAD52 Recombination Protein and Methods Using Same
EP2128157A1 (en) Heterocyclidene-n-(aryl)acetamide derivative
US20170334842A1 (en) Inhibitors of the mitf molecular pathway
US11987579B2 (en) Niclosamide analogues and therapeutic use thereof
WO2020210662A1 (en) Small molecules for cancer therapy that reduce the expression of transcription factors klf5 and egr-1
US20180155320A1 (en) 2-oxo-1,2-dihydropyridine-3-carboxamide compounds and their use as inhibitors of pdk1
EP3878841A1 (en) Indazole kinase inhibitor and use thereof
JP2001504839A (ja) α―２アドレナリン受容体作動薬として有用なグアニジニルアミノ複素環式化合物
CN118994142A (zh) 呋喃酰胺类化合物及其应用
CA3152424A1 (en) Quinoline inhibitors of rad52 and methods of use
CN116535361A (zh) 取代羟基嘧啶类黄嘌呤氧化酶抑制剂及其制法和药物用途
WO2021168341A1 (en) Solid forms of 1-(5-(3-(7-(3-fluorophenyl)-3h-imidazo[4,5-c]pyridin-2-yl)-1h-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-yl)-n,n-dimethylmethanamine
Zeng et al. Discovery of Novel Triazine Derivatives as Potent and Orally Bioavailable Pi3k/Mtor Dual Inhibitors for the Treatment Of Gefitinib Resistance in Non-Small Cell Lung Cancer

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130419

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140507

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20140507

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20150514

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20150706

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20151130